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Background: There have been several reports that statin therapy is associated with a
slightly higher incidence of new-onset diabetes mellitus(DM) or impaired glucose
intolerance(IGT). It is still controversial whether the chronic statin therapy is a risk factor
of IGT and new onset DM, in Asian population.
Methods: We investigated the 13,561 patients(pts) that was HbA1c level 6.0% and
fasting glucose level124 mg/dL(statin therapy group4016 and control group9545).
To adjust potential confounders including age, gender, hypertension, hyperlipidemia,
chronic kidney disease, hyper/hypo-thyroidism, lipid profile, beta-blocker, diuretics, a
propensity score matched analysis was performed using the logistic regression model. The
primary end-point was the cumulative incidence of new-onset DM, IGT, and impaired
fasting glucose(IFG). Also, Multivariable Cox-regression analysis adjusted aforemen-
tioned variables was performed to determine the impact of statin therapy on the incidence
of new-onset DM, IGT, and IFG.
Results: Mean follow-up duration was 534604 days in all group, and 608607 days
in propensity score matching group. Baseline characteristics was similar between the two
groups except hyperlipidemia (11.1% vs. 3.5%, p0.001). In Kaplan-Meyer curve, there
was no difference between the two groups (p0.501, figure A). Also, in cox-regression
analysis performed in all pts, statin therapy was not associated with the increased
incidence of primary end-point(figure B).
Conclusions: In our study, there was no clear association with statin therapy and IGT and
new-onset DM in a series of cardiovascular pts in Asian population.
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Background: Introduction Few data is available on the comparison between diabetic and
non-diabetic patients after percutaneous coronary intervention (PCI) with drug eluting
stents for unprotected left main coronary artery disease. Hypothesis We assessed the
hypothesis that diabetes mellitus is a predictor of worse clinical outcome after PCI with
drug eluting stents for unprotected left main disease.
Methods: This is a multicenter registry enrolling consecutive patients undergoing PCI
with paclitaxel or everolimus-eluting stents for unprotected left main disease. Death,
cardiac death, myocardial infarction (MI), clinically-driven-target lesion revascularization
(TLR), target vessel revascularization (TVR), stroke, definite/probable stent thrombosis
were assessed at 2-year follow-up. A multiple cox regression analysis was performed.
Hazard ratios (HR) with 95% confidence interval (CI) were calculated.
Results: A total of 331 patients, median age 71 yrs-old, (25th-75th percentile 62-78), 87
(26.3%) diabetics, 172 undergoing paclitaxel eluting stent and 159 undergoing everolimus
eluting stent implantation, were enrolled. At 2-year follow-up diabetics, as compared to
non-diabetic patients, presented a higher incidence of death (14.9% vs 4.5%, p0.001),
cardiac death (9.2% vs 2.9%, p0.015), stroke (5.7% vs 0.8%, p0.015), definite/probable
stent thrombosis (3.4% vs 0%, p0.018), the composite of death/MI/stroke, (21.8% vs 9.8%,
p0.004), the composite of death/MI/TLR (22.9% vs 13.1%, p0.03), and the composite of
death/MI/TLR/stroke (25.3% vs 13.5%). No significant differences between diabetics and
non-diabetic patients were found with respect to MI (10.3% vs 6.1%, p0.19), TLR (6.9% vs
4.9%, p0.48) or TVR (16.1% vs 9.4%, p0.09). At multiple cox regression analysis,
diabetes status was a significant predictor of death/MI/stroke (HR 2.39, 95% CI 1.30-4.37,
p0.005), of death/MI/TLR (HR 1.97, 95% CI 1.12-3.46, p0.018) and of death/MI/TLR/
stroke (HR 2.08, 95% CI 1.21-3.58, p0.008).
Conclusions: In patients undergoing PCI with drug eluting stents for unprotected left
main coronary artery disease, diabetes status is associated with a significantly worse
prognosis at 2-year follow-up.
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Background: Plain Old Balloon Angioplasty (POBA) for In-Stent Restenosis (ISR) in
the superficial femoral artery (SFA) and proximal popliteal artery (PA) has a recurrent
stenosis rate of up to 70% within 12 months. Aim of the study was to test the ability to
reduce this high recurrency rate with a Paclitaxel Eluting Balloon (PEB).
Methods: Since January 2010, 44 consecutive patients with symptomatic in-stent restenosis
of the SFA or proximal PA were treated with PEB (Admiral In.Pact, Medtronic, Minnesota,
USA). The occurrence of re-restenosis and repeat intervention at 1-year follow up was
compared to those of 42 consecutive patients treated with POBA from January 2008 to
December 2009.
Results: No significant difference in terms of clinical, angiographic and procedural charac-
teristics were observed among the two study groups. Respectively: Age 7411 in PEB vs
767 in POBA, P0.1; insuline therapy 23/44(50%) vs 21/42(48%), p0.9; Rutherford
Class4 33/44(75%) vs 28/42(67%), p0.8; serum creatinine 1.091.5mg/dL vs
1.021.5mg/dL, p0.9; occlusive ISR 23/44(52%) vs 28/42(66%), p0.1; restenosis length
13186mm vs 13885mm, p0.4. Procedural success, defined as a residual stenosis 30%
in the restenotic segment (stent	5mm of proximal and distal edges), was obtained in all treated
lesions and no adverse clinical events occurred during hospitalization in both groups. At
one-year follow-up, 6 patients died (3 in PEB and 3 in POBA), one patient in POBA group
underwent major amputation. Restenosis, assessed by angiography or ultrasound, occurred in
8/41(19%) PEB vs 28/39(72%) POBA, p0.05. Repeat angioplasty for symptomatic in stent
re-restenosis occurred in 6/44(13%) PEB vs 13/42(31%) POBA, p0.05.
Conclusions: Repeat balloon angioplasty for ISR in the SFA and proximal PA artery
using PEB showed a significant reduction in re-restenosis and repeat angioplasty
compared to POBA at 1-year follow-up.
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Background: Diabetic patients (DP) show more complex coronary artery disease than
non-diabetic patients (N-DP) and diabetes mellitus (DM) predicts adverse outcome after
MI. We sought to investigate the interaction of reperfusion and DM on mortality after
STEMI treated with primary PCI.
Methods: A multicenter registry of consecutive patients treated with primary PCI in 3
centers. Vital status was obtained through municipality records. Reperfusion was scored
by TIMI flow. Cox regression was used to analyze effect modification of the correlation
between sub-optimal reperfusion (TIMI3) and mortality by DM.
Results: In total, 386 DP and 3063 N-DP were treated with primary PCI. DP were older
(66.7 vs. 62.8 years in N-DP, p0.001), less often male (68.4% vs. 75.9% in N-DP,
p0.001), more frequently suffered a previous MI (14.3% in DP vs. 10.3% N-DP,
p0.018) and renal insufficiency (12.5% vs. 2.6% in N-DP, p0.001). Moreover, DP
showed more multi-vessel disease (31.3% vs. 20.3% in N-DP, p0.001). TIMI flow
before and after PCI was similar. Mortality was higher in DP (30 day: 9.1% vs. 3.8% in
N-DP, p0.001, 1 year: 14.5% in DP vs. 6.1% in N-DP, p0.001). Furthermore, DP
patients showed substantially worse 1 year mortality after sub-optimal reperfusion
compared to N-DP (figure), an interaction which was confirmed by cox regression
(interaction HR 2.36, 95% CI 1.11-5.03 after correction for confounders).
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Conclusions: Sub-optimal TIMI flow is of greater prognostic value in DP compared to
N-DP, stressing the importance of optimal reperfusion after primary PCI for STEMI in DM.
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Background: The purpose of this study was to assess the impact of body mass index
(BMI) and diabetes mellitus (DM) on angiographic outcomes in patients treated with
different drug-eluting stents.
Methods: From November 2002 to March 2011, 8567 de novo coronary lesions
were treated with drug-eluting stent. Dialysis patients were excluded. Of 8567
lesions, 1934 lesions were treated with everolimus-eluting stent (EES), 1215 with
paclitaxel-eluting stent (PES), and 5418 with sirolimus-eluting stent (SES).
Angiographic follow-up was routinely performed at 8 months after successful
procedure. The follow-up rate was 81%. The patients were classified as under-
weight (BMI 20), normal weight (BMI 20 and 25), and overweight (BMI
25). The patients were divided into three groups according to implanted stent
type: EES, PES, and SES. Of all patients, 42% were with DM, of whom 11% were
insulin-dependent. The rates of DM and insulin treatment were similar in all
groups. Angiographic outcomes were compared between each group.
Results: Independent predictors of binary restenosis differed in each group. In the
SES group, they were BMI (depression of 5 kg/m2), DM, bifurcation, chronic
total obstruction (CTO), stent size 2.5 mm, and lesion length 20 mm. In the PES
group, they were BMI (depression of 5 kg/m2), DM, and stent size 2.5 mm. In the
EES group, they were CTO, stent size 2.5 mm, and lesion length 20 mm. The
figure shows odds ratio of BMI (depression of 5 kg/m2) and DM between each
group.
Conclusions: BMI and DM affect angiographic outcomes in patients treated with SES
and PES but not those in patients treated with EES.
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Background: Diabetes mellitus is known as a strong predictive factor of adverse
cardiovascular event after ST-segment elevation myocardial infarction (STEMI). Re-
cently, glycosylated hemoglobin (HbA1c) reflecting serum glucose control within 8 to 12
weeks, is studied to investigate relationship with major adverse cardiac events (MACE)
after acute myocardial infarction. This study is conducted to determine the association
between follow-up HbA1c and MACE in diabetic patients with STEMI undergoing
primary percutaneous coronary intervention (PCI).
Methods: Using data from Korea Working Group on Myocardial Infarction, 303
diabetic patients with STEMI undergoing primary PCI were enrolled. Patients
were divided into three groups based on follow-up HbA1c(FU-HbA1c): optimal,
FU-HbA1c 7%; suboptimal, 7%FU-HbA1c9%, poor controlled group,
9%FU-HbA1c. We analyzed 12-month cumulative MACE, defined as a com-
posite of mortality, nonfatal myocardial infarction, re-PCI or coronary artery
bypass graft in each group. Also, we investigated the value of FU-HbA1c to
predict MACE using multivariate logistic regression analysis.
Results: The mean duration of HbA1c and clinical event follow-up was 5 and 12 months,
respectively. The incidence rate of 12-month cumulative MACE were significantly
different in each group: 7.3% vs 13.0% vs 23.9%, respectively (p0.005), which was
mainly due to increased repeated PCI. In multivariate logistic analysis, the factor of
FU-HbA1c more than 9.0% was shown to be independently associated with 12-month
cumulative MACE, and compared with FU-HbA1c7.0%: OR 11.437, 95% confidence
interval 1.709-76.522, p0.012.
Conclusions: This study suggests that FU-HbA1c in early phase was associated
with higher incidence of 12-month cumulative MACE, mainly contributing to
increased repeated PCI in diabetic patients with STEMI undergoing primary PCI.
And more than 9% of FU-HbA1c was identified to be an independent predictor of
adverse outcome. These imply continuous tight monitoring of serum glucose in
early phase after myocardial ischemic insult is important to reduce the possibility
of repeated PCI following restenosis, but more research is needed to understand
these findings with long-term clinical data.
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Background: Diabetes is associated with an increased risk of major adverse cardiac
events (MACE) following percutaneous coronary intervention.
Methods: We compared clinical outcomes in patients with and without diabetes
mellitus treated with the third-generation biolimus-eluting Nobori stent (BES) or
the first-generation sirolimus-eluting Cypher™ Select	 stent (SES) in the SORT
OUT V trial. We randomized 2.468 patients to treatment with BES (n1.229,
diabetes: n185) or SES (n1.239, diabetics: n189) and followed them for 12
months. Randomization was stratified by presence/absence of diabetes. The
primary endpoint was MACE, defined as a composite of cardiac death, myocardial
infarction (MI), or target vessel revascularization (TVR). Secondary endpoints
were each of these individual endpoints plus all-cause mortality, target lesion
revascularization (TLR), and definite stent thrombosis.
Results: In diabetic patients, use of BES compared with SES was neither
associated with an increased risk of MACE (6.6% vs. 8.0%; hazard ratio (HR) 
0.83, 95% confidence interval (CI): 0.39-1.77), MI (1.6% vs. 1.6%, HR  1.02,
95% CI: 0.21-5.08), TVR (5.9% vs. 4.8%; HR  1.27, 95% CI: 0.52-3.05), nor
TLR (5.4% vs. 3.2%; HR  1.72, 95% CI: 0.63-4.74). Similarly, patients without
diabetes, MACE (5.1% vs. 3.7%; hazard ratio (HR)  1.38, 95% CI: 0.91-2.08.),
MI (1.4% vs. 0.8%, HR  1.89, 95% CI: 0.80-4.47), TVR (3.8% vs. 2.8%; HR 
1.40, 95% CI: 0.87-2.25), and TLR (2.8% vs. 1.8%; HR  1.55, 95% CI: 0.87-2.76)
showed no differences between the two stents. With regard to definite stent
thrombosis, BES was neither associated with fewer events in patients with diabetes
(2.2% vs. 1.2%; HR  2.05, 95% CI: 0.38-11.2) nor in patients without diabetes
(0.6% vs. 0.2%; HR  3.03, 95% CI: 0.61-15.0).
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